11.22.19
6 min. read

Proteus headcount dip. Smart pill standards.

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Issue 029.

Get E&O weekly. | Subscribe | Digital health research from Brian Dolan.

Welcome to E&O.

Last week's newsletter had a glass-is-more-than-half-full 55 percent open rate. Here's what's happening this week:

  • I spent most of Thursday just outside of Washington DC at a workshop convened by IEEE and US Pharmacopeia focused on thinking through standards for smart pills -- sometimes called digital pills, signaling pills, or as FDA-savvy lawyers call them, ingestible event markers. A few initial thoughts and findings from that below.
  • This slide deck and these presentation notes from Princeton University computer science professor Arvind Narayanan make for a great primer on how to cut through AI hype. It's not healthcare-specific but references some medical use cases. He breaks down AI claims into the genuine, the far from perfect but improving, and the dubious.
  • You probably read this
×

Recent Articles